All In MedTech

FDA Clearance Tracker · P000044

VITROS IMMUNODIAGNOSTIC PRODUCTS/HBSAG REAGENT PACK,VITROS IMMUNODIAGNOSTIC PRODUCTS CONFIRMATORY KIT, AND VITROS IMMUNR

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Apr 27, 2001 (this decision)Source: openFDAMethods & limitations

PMA

The decision

FDA number
P000044
Device name
VITROS IMMUNODIAGNOSTIC PRODUCTS/HBSAG REAGENT PACK,VITROS IMMUNODIAGNOSTIC PRODUCTS CONFIRMATORY KIT, AND VITROS IMMUNR
Applicant location
Rochester, NY
Received
Nov 1, 2000
Decided
Apr 27, 2001
Decision
Approved (reclassified)
Supplements
40 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class II
Regulation
21 CFR 866.3172

Every decision under product code LOM

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE VITROS IMMUNODIAGNOSTIC PRODUCTS HBSAG REAGENT PACK, VITROS IMMUNODIAGNOSTIC PRODUCTS CONFIRMATORY KIT, AND VITROS IMMUNODIAGNOSTIC PRODUCTS CALIBRATOR. THE VITROS IMMUNODIAGNOSTICS HBSAG REAGENT PACK IS INDICATED FOR THE IN VITRO QUALITATIVE DETECTION OF HEPATITIS B SURFACE ANTIGEN (HBSAG) IN HUMAN SERUM AND PLASMA (HEPARIN, EDTA, AND SODIUM CITRATE) USING THE VITROS ECI IMMUNODIAGNOSTIC SYSTEM. ASSAY RESULTS, IN CONJUNCTION WITH OTHER SEROLOGICAL AND CLINICAL INFORMATION, MAY BE USED FOR THE LABORATORY DIAGNOSIS OF INDIVIDUALS WITH ACUTE OR CHRONIC HEPATITIS B. IN ADDITION, THIS ASSAY MAY BE USED TO SCREEN FOR HEPATITIS B INFECTION IN PREGNANT WOMEN TO IDENTIFY NEONATES WHO ARE AT HIGH RISK OF ACQUIRING HBV DURING THE PERINATAL PERIOD. THE VITROS IMMUNODIAGNOSTIC PRODUCTS HBSAG CALIBRATOR IS INDICATED FOR USE IN THE CALIBRATION OF THE VITROS IMMUNODIAGNOSTIC SYSTEM FOR THE QUALITATIVE IN VITRO DETERMINATION OF HEPATITIS B SURFACE ANTIGEN (HBSAG) IN HUMAN SERUM OR PLASMA (HEPARIN, EDTA, AND SODIUM CITRATE) USING VITROS HBSAG REAGENT PACKS. THE VITROS HBSAG CALIBRATOR HAS BEEN VALIDATED FOR USE ONLY ON THE VITROS SYSTEM WITH THE VITROS IMMUNODIAGNOSTIC PRODUCTS HBSAG REAGENT PACK. REFER TO THE VITROS HBSAG REAGENT PACK INSTRUCTIONS FOR USE FOR FURTHER DETAILS. THE VTIROS HBSAG CONFIRMATORY KIT IS INDICATED FOR THE QUALITATIVE CONFIRMATION OF HEPATITIS B SURFACE ANTIGEN (HBSAG) IN HUMAN SERUM AND PLASMA (HEPARIN, EDTA, AND SODIUM CITRATE) SPECIMENS THAT HAVE BEEN FOUND TO BE REPEATEDLY REACTIVE USING THE VITROS IMMUNODIAGNOSTIC PRODUCTS HBSAG REAGENT PACK AND THE VITROS IMMUNODIAGNOSTIC PRODUCTS HBSAG CALIBRATOR. THE VITROS HBSAG CONFIRMATORY KIT IS FOR USE WITH THE VITROS ECI IMMUNODIAGNOSTIC SYSTEM.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code LOM. The earliest in FDA's data is P780016-S002, decided Mar 17, 1980.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Ortho-Clinical Diagnostics, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.